# Isomorphic Labs Raises $5 Billion in Series C for AI Drug Development

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/59487
Published: 2026-11-17T14:34:23.000Z
Updated: 2026-11-17T14:34:23.000Z
Section: Business

> Greenoaks and Sequoia Capital co-led the round, with Andreessen Horowitz and Alphabet also investing.

Isomorphic Labs raised $5 billion in a Series C round to expand its AI drug-design work and move its first therapeutic programs closer to clinical trials.

Greenoaks and Sequoia Capital co-led the round, with Andreessen Horowitz and Alphabet also investing.

The new funding follows a $2.1 billion Series B round in May. Isomorphic plans to expand its drug-design system, develop new AI models and deepen its research into disease biology.

Its first therapeutic programs are moving toward clinical trials.

Demis Hassabis, Isomorphic’s founder and CEO, has led the company since it was launched from DeepMind in 2021. Following an Aug. 5 leadership change, he became chairman of Google DeepMind and chief scientist at Alphabet while continuing to run Isomorphic.


